Pharmaxis Ltd (AU:SNT) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Syntara Limited, a clinical stage drug development company listed on the ASX, is set to update investors in an upcoming webinar, highlighting its promising pipeline including the lead candidate SNT-5505 for myelofibrosis. The company is advancing several phase 2 studies in high unmet need areas, while also collaborating on treatments for neurodegenerative diseases and fibrosis. With a strong focus on innovation, Syntara aims to make significant strides in treating complex conditions.
For further insights into AU:SNT stock, check out TipRanks’ Stock Analysis page.
